Reaching Diverse Patient Populations To Drive Inclusivity In Trials

With a litany of factors influencing individual patient outcomes and access to healthcare, there is a clear disparity in how many of these groups are represented in clinical studies; the FDA recently concluded that 80% of clinical trial participants are white. Furthermore, less than 20% of approved drugs are backed by data reflecting treatment efficacy for Black patients.

In short, there is a considerable diversity gap in clinical research, compounded further by three key barriers: patient trust, patient awareness, and patient access. Eradicating these barriers is imperative to facilitating trial diversity and, ultimately, health equity. In order to pursue effective diversity strategies in clinical trial recruitment, it is critical to understand these barriers and develop a plan of action to remove them.